Gapping down
In reaction to earnings/guidance:
- VIPS -2.3% (lowers Q4 revenue guidance)
Other news:
- KNSA -18.3% (Phase 3 portion of the Phase 2/3 trial of mavrilimumab in COVID-19-related acute respiratory syndrome did not meet the primary efficacy endpoint )
- BTCM -3.6% (appoints Bo Yu as Chairman)
- RRD -1.6% (recently identified a systems intrusion)
- MRNA -1% (announces revised supply agreement with S Korea for 20 mln doses)
- VXX -1% (trading lower with US futures in record territroy)
Analyst comments:
- INNV -3% (downgraded to Neutral from Buy at Goldman)